HBRI is committed to working with industry as part of its mission to ensure that inventions and technologies are brought to the market for the benefit of society. HBRI partners with for-profit and non-profit groups to help promote research and develop products from intellectual property discovered and developed at the Institute.

HBRI’s reputation as a leading research institute comes in part from its success at developing drug candidates for diseases that cause human suffering. The approach has afforded new drug candidates and research aimed at the development of new drugs and therapies. HBRI discoveries have included new compounds for treating cardiac disease, bone disease, and neuronal disease including Alzheimer’s and neurodegenerative diseases, drug abuse, alcoholism, smoking and inflammation. In addition, HBRI has developed novel approaches for using stem cells for therapeutic purposes in human diseases as well as biomarker signatures for human diseases.

In the past, HBRI has participated in six Investigational New Drug (IND) applications. Five have been approved as drugs and are available in the US and elsewhere today. One drug candidate is in front of the FDA for approval.

The HBRI Office of Business Development can discuss how interaction with HBRI can have a major impact on your company’s competitiveness and productivity. Industry partners engage with HBRI as licensees of patented technologies or tangible materials. Other partners are collaborators with HBRI faculty or are sponsors of research. The HBRI Office of Business Development is here to facilitate the approach most appropriate for your company.

Bringing scientific discoveries to collaborators and developing research partners in the for-profit sector is an end-product of research done at the Institute. While the goal of HBRI is not to develop products to sell, HBRI encourages collaborations and partnerships with other groups that have an interest in developing intellectual property discovered at the HBRI for the good of society. For more information, contact the scientists involved in the discovery or contact the intellectual property contact indicated at